RJA
AIMT

Raymond James & Associates’s Aimmune Therapeutics AIMT Stock Holding History

Raymond James & Associates’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-28,349
Closed -$474K – 3745
2020
Q2 		$474K Buy
28,349
+16,727
+144% +$284K ﹤0.01% 2620
2020
Q1 		$168K Sell
11,622
-16,237
-58% -$415K ﹤0.01% 3092
2019
Q4 		$932K Buy
27,859
+2,274
+9% +$63.6K ﹤0.01% 2306
2019
Q3 		$536K Sell
25,585
-15,980
-38% -$326K ﹤0.01% 2602
2019
Q2 		$865K Sell
41,565
-12,399
-23% -$255K ﹤0.01% 2300
2019
Q1 		$1.21M Buy
53,964
+7,581
+16% +$178K ﹤0.01% 2086
2018
Q4 		$1.11M Sell
46,383
-4,959
-10% -$128K ﹤0.01% 2023
2018
Q3 		$1.4M Sell
51,342
-2,766
-5% -$78.2K ﹤0.01% 2031
2018
Q2 		$1.46M Buy
54,108
+5,612
+12% +$172K ﹤0.01% 1969
2018
Q1 		$1.54M Buy
48,496
+23,759
+96% +$836K ﹤0.01% 1855
2017
Q4 		$936K Buy
24,737
+1,669
+7% +$53.9K ﹤0.01% 2163
2017
Q3 		$572K Buy
23,068
+51
+0.2% +$1.1K ﹤0.01% 2403
2017
Q2 		$473K Buy
23,017
+4,982
+28% +$95K ﹤0.01% 2452
2017
Q1 		$392K Buy
18,035
+775
+4% +$15.9K ﹤0.01% 2539
2016
Q4 		$353K Buy
17,260
+126
+0.7% +$2.58K ﹤0.01% 2541
2016
Q3 		$257K Buy
17,134
+4,843
+39% +$65.4K ﹤0.01% 2718
2016
Q2 		$133K Sell
12,291
-65
-0.5% -$883 ﹤0.01% 2751
2016
Q1 		$168K Buy
+12,356
New +$193K ﹤0.01% 2620

Other funds holding AIMT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Raymond James & Associates's AIMT Position: Q3 2020 in Review

Raymond James & Associates sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 28,349 shares — an estimated $474K sold.

Raymond James & Associates first reported a position in AIMT in Q1 2016 and held it in 18 quarters. The position peaked at $1.54M in Q1 2018. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

  • Raymond James & Associates reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Raymond James & Associates sold 28,349 Aimmune Therapeutics shares in Q3 2020, an estimated $474K.
  • Raymond James & Associates first reported a position in Aimmune Therapeutics in Q1 2016 and held it in 18 quarters.
  • Raymond James & Associates's Aimmune Therapeutics position peaked at $1.54M in Q1 2018.
  • 188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on Raymond James & Associates's 13F filing for Q3 2020, filed 4 Nov 2020.